Table 3.
Multivariate analysis (Cox proportional hazards model) in the subsets of AML patients with Ara-C induction therapy and HDAC consolidation therapy: OS (HSCT-censored) and EFS (HSCT-censored)
| OS HSCT-censored | EFS HSCT-censored | |||||
|---|---|---|---|---|---|---|
| AC ind.a | HDAC cons.b | AC ind. MDACCc | AC ind. | HDAC cons. | AC ind. MDACC | |
| HRd (95% CI; p-value) | HR (95% CI; p-value) | HR (95% CI; p-value) | HRd (95% CI; p-value) | HR (95% CI; p-value) | HR (95% CI; p-value) | |
| Unadjusted | 1.009 (1.000–1.017; 0.044) | 1.014 (1.004–1.024; 0.007) | 1.011 (1.000–1.022; 0.049) | 1.008 (1.001–1.015; 0.022) | 1.012 (1.004–1.020; 0.003) | 1.009 (1.000–1.017; 0.049) |
| Adjusted for age, gender, risk group, FLT3-TKD | 1.007 (0.997–1.018; 0.159) | 1.010 (0.999–1.022; 0.078) | 1.009 (0.998–1.020; 0.117) | 1.008 (1.000–1.017; 0.040) | 1.011 (1.002–1.020; 0.014) | 1.009 (1.000–1.018; 0.039) |
| Adjusted for age, gender, risk group, NPM1 | 1.006 (0.995–1.017; 0.266) | 1.008 (0.996–1.020; 0.196) | 1.009 (0.997–1.021; 0.147) | 1.008 (0.999–1.017; 0.075) | 1.010 (1.000–1.020; 0.047) | 1.008 (0.998–1.018; 0.102) |
aPatients receiving AraC induction treatment
bPatients receiving high-dose AraC consolidation therapy
cPatients in the M.D. Anderson cohort receiving AraC induction therapy, not adjusted for risk group, due to all patients belonging to the intermediate risk group
dHazard Ratio (HR) for a one-unit increase in SAMHD1 percent positive blasts